Valuation: Circio Holding ASA

Market Cap 3.15B 335M 299M 276M 252M 470M 31.83B 480M 3.31B 1.3B 16.61B 1.26B 1.23B 52.89B P/E 2024
0.25x
P/E 2025 -2.65x
Enterprise Value 3.16B 336M 299M 276M 252M 470M 31.86B 480M 3.31B 1.3B 16.62B 1.26B 1.23B 52.93B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
74.23%
Yield 2024 *
-
Yield 2025 -
1 day-1.10%
1 week-2.87%
Current month-2.35%
1 month-8.46%
3 months+40.16%
6 months+33.58%
Current year+829.55%
1 week 10.54
Extreme 10.54
11.1
1 month 9.92
Extreme 9.92
11.78
Current year 0.98
Extreme 0.978
15.7
1 year 0.87
Extreme 0.869999
15.7
3 years 0.48
Extreme 0.48
15.7
5 years 0.48
Extreme 0.48
202.5
10 years 0.48
Extreme 0.48
1,017
Manager TitleAgeSince
Chief Executive Officer - 2021-10-19
Director of Finance/CFO 58 2022-03-06
Chief Tech/Sci/R&D Officer - 2021-12-31
Director TitleAgeSince
Director/Board Member 79 2015-06-30
Director/Board Member 66 2015-09-13
Chairman 64 2020-04-28
Date Insider Type Main position Quantity % Market Cap. Importance
11/30/21 Exercice

Chief Executive Officer

120,000 0.1386%
5/19/21 Buy

Director

21,299 0.0246%
12/3/20 Buy

Chief Technology Officer

10,000 0.0116%
Change 5-day change 1-year change 3-year change Capi.($)
-1.10%-2.87%+766.99%+33.58% 338M
+1.52%-7.16%+51.66%+67.41% 65B
+1.52%+7.17%+10.77%+77.89% 51.2B
+0.30%+0.19%+2.53%+56.14% 51.19B
-0.38%+2.31%+29.98%+40.71% 43.93B
+0.30%+4.43%+16.99%+120.94% 41.96B
+2.35%-4.01%+236.69%+497.21% 38.14B
+2.16%+10.36%+18.92%+59.70% 33.24B
-0.90%-10.49%+37.09%+1.80% 25.2B
+1.60%+3.97%+21.34%+22.33% 22.5B
Average +0.74%-0.05%+119.29%+97.77% 37.27B
Weighted average by Cap. +0.97%+0.04%+46.68%+106.29%

Financials

2024 2025
Net sales - -
Net income 57.52M 6.12M 5.45M 5.04M 4.59M 8.57M 581M 8.75M 60.38M 23.78M 303M 22.95M 22.46M 965M -45.91M -4.88M -4.35M -4.02M -3.66M -6.84M -463M -6.98M -48.19M -18.97M -242M -18.32M -17.92M -770M
Net Debt -972K -103K -92.06K -85.12K -77.57K -145K -9.81M -148K -1.02M -402K -5.12M -388K -379K -16.3M 2.24M 239K 213K 197K 179K 334K 22.66M 342K 2.36M 928K 11.82M 896K 876K 37.65M
Projected Income Statement - Annual - Circio Holding ASA
Logo Circio Holding ASA
Circio Holding ASA, formerly Targovax ASA, is a Norway-based company active within the healthcare sector. The Company is engaged in the biotechnology and develops ribonucleic acid (RNA) and immunotherapy medicines. The Company offers circular RNA (circRNA) platform to develop circRNA medicines for cancer, vaccines, protein replacement for genetic disorders and cell therapy. The circVec technology is based on a modular genetic cassette design for efficient biogenesis of multifunctional circRNA from DNA-based vectors that can be deployed for multiple purposes. Circios strategy is to develop circAde cancer medicines in-house and seek partnerships in other therapeutic areas to demonstrate the broad potential of the circVec platform and accelerate circRNA pipeline development. Circio’s second clinical program is an immunotherapy targeting KRAS driver mutations.
Employees
11
Date Price Change Volume
26-10-19 NOK 10.82 -1.10% 1,041,028
26-10-16 NOK 10.94 +0.74% 1,951,617
26-10-15 NOK 10.86 -0.37% 1,956,479
26-10-14 NOK 10.90 -0.18% 1,345,022
26-10-13 NOK 10.92 -1.09% 1,827,284

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Circio Holding ASA
  1. Stock Market
  2. Stocks
  3. TRVX Stock